Oncodesign Precision Medicine (XPAR:ALOPM) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Oncodesign Precision Medicine had a gross margin of -983.19% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Oncodesign Precision Medicine Gross Margin % Related Terms
Oncodesign Precision Medicine Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine Gross Margin % Chart
XPAR:ALOPM vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Oncodesign Precision Medicine (XPAR:ALOPM) has a Gross Margin % of -983.19% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Oncodesign Precision Medicine and its competitors. According to the industry distribution chart, Oncodesign Precision Medicine ranks #2 out of 731 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Oncodesign Precision Medicine's Gross Margin % too high?
Oncodesign Precision Medicine's current Gross Margin % is -983.19%. Based on the distribution chart, Oncodesign Precision Medicine ranks #2 out of 731 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 33/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #2 out of 731 companies for Gross Margin %. This places Oncodesign Precision Medicine in the top 0% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 731 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current Gross Margin % is -983.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.29, compared to a current price of €0.34 — trading 18.3% above its estimated fair value. The current Gross Margin % is -983.19%. Oncodesign Precision Medicine's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current Gross Margin % is -983.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.34 is trading 18.3% above its estimated GF Value™ of €0.29.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for XPAR:ALOPM:
Gross Margin %: -983.19%
GF Value™: €0.29 vs. price of €0.34 (18.3% above fair value)
No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score
Get the complete analysis for XPAR:ALOPM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALOPM has been successfully added to your 
